MedicalResearch.com Interview with: Brett King, MD, PhD, FAAD Associate Professor of Dermatology Yale School of Medicine MedicalResearch.com:  What is the background for this study?  Response: Alopecia areata is an autoimmune disorder marked by disfiguring, non-scarring hair loss, and there are no therapies approved by the U.S. Food and Drug Administration for treatment of the disease. JAK inhibitors are showing promise for treatment of severe alopecia areata. In this work, the pooled results of two phase 3 clinical trials of the JAK inhibitor baricitinib were reported out to 52 weeks. (more…)